Analysis of the pharmacological mechanism and effects of cabergoline

Cabergoline is a dopamine receptor agonist that mainly acts on D2 receptors and plays an important role in the treatment of hyperprolactinemia, Parkinson's disease and other diseases. Its structure belongs to the ergot compound, which has high selectivity and long action time, so it is widely used in clinical practice, especially in the treatment of pituitary prolactinoma.

In terms of pharmacological mechanism, cabergoline inhibits the secretion of prolactin (PRL) by stimulating the dopamine D2 receptors in the hypothalamus and anterior pituitary gland. Since the secretion of prolactin is strongly inhibited by dopamine, when the D2 receptor is activated, the secretory activity of pituitary prolactin cells is inhibited, thereby reducing the serum prolactin level and improving symptoms caused by excessive prolactin, such as galactorrhea, amenorrhea, infertility, etc.

Compared with traditional bromocriptine (Bromocriptine), cabergoline has a longer half-life (up to 65 hours). The efficacy can usually be maintained by taking 1-2 times a week, reducing the patient's medication burden and the incidence of side effects. In addition, it causes less irritation to the gastrointestinal tract and is better tolerated, making it especially suitable for long-term treatment of patients with hyperprolactinemia.

Of note, cabergoline is also used to treat diseases related to dopamine dysfunction, such as Parkinson's disease. However, during use, attention should be paid to possible side effects such as heart valve disease, hypotension, and hallucinations. Therefore, it should be used clinically with caution based on individual circumstances, and heart valve function should be monitored regularly. Overall, cabergoline occupies an important position in the field of endocrine therapy due to its high efficiency, long-lasting effect and good tolerance.

Reference materials:https://my.clevelandclinic.org/health/drugs/20863-cabergoline-tablets